Last reviewed · How we verify
HLA-matched VSTs
HLA-matched VSTs is a Biologic drug developed by Baylor College of Medicine. It is currently in Phase 1 development.
HLA-matched Virus Specific T-cells (VSTs) are being studied as a treatment for various viral infections, including Cytomegalovirus Infections, Adenovirus Infection, and EBV Infection, among others. The use of HLA-matched VSTs is being investigated in clinical trials, such as NCT03475212, for their potential to enhance T-cell reconstitution before or after hematopoietic stem cell transplantation.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HLA-matched VSTs |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. (PHASE1)
- TETRAVI Expanded Access Program
- Allogeneic Virus-specific T Cell Lines (VSTs) (PHASE1)
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (PHASE1, PHASE2)
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT (PHASE1, PHASE2)
- Anti-SARS Cov-2 T Cell Infusions for COVID 19 (PHASE1)
- Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLA-matched VSTs CI brief — competitive landscape report
- HLA-matched VSTs updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI
Frequently asked questions about HLA-matched VSTs
What is HLA-matched VSTs?
Who makes HLA-matched VSTs?
What development phase is HLA-matched VSTs in?
Related
- Manufacturer: Baylor College of Medicine — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing